REGISTERED
on 16 Feb 2021
Last Applicant/ Owned by
121 Locust St SW
Vienna
VA
22180
Serial Number
88768088 filed on 21st Jan 2020
Registration Number
6274061 registered on 16th Feb 2021
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
NOURIN
protein arrays for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for medical diagnosis purposes; protein arrays for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-g Read More
Classification Information
Class [001]
Chemical Products
protein arrays for research purposes; gene-based RNA molecular network being RNA sequences for research purposes; protein arrays for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for research purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for research use; diagnostic biomarker reagents for research purposes; protein arrays of biomarker reagents for research purposes; gene-based RNA molecular network biomarker reagents for research purposes; protein arrays and gene-based RNA molecular network biomarker reagents for research purposes; tissue-derived diagnostic biomarker reagents for research purposes; cardiac-derived diagnostic biomarker reagents for research purposes
First Use Date in General
19th Oct 2020
First Use Date in Commerce
19th Oct 2020
Class [005]
Pharmaceutical Products
protein arrays for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for medical diagnosis purposes; protein arrays for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for medical use; diagnostic biomarker reagents for medical purposes; protein arrays of biomarker reagents for medical diagnosis purposes; gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; protein arrays and gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; tissue-derived diagnostic biomarker reagents for medical purposes; cardiac-derived diagnostic biomarker reagents for medical purposes
First Use Date in General
19th Oct 2020
First Use Date in Commerce
19th Oct 2020
Mark Details
Serial Number
No 88768088
Mark Type
No Service/Collective Mark
Attorney Docket Number
No TTA54611
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 16th Feb 2021 | REGISTERED-PRINCIPAL REGISTER |
| 15th Jan 2021 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| 14th Jan 2021 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| 14th Jan 2021 | STATEMENT OF USE PROCESSING COMPLETE |
| 13th Jan 2021 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 22nd Dec 2020 | USE AMENDMENT FILED |
| 22nd Dec 2020 | TEAS STATEMENT OF USE RECEIVED |
| 04th Aug 2020 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 09th Jun 2020 | PUBLISHED FOR OPPOSITION |
| 09th Jun 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |